JP2019533449A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533449A5 JP2019533449A5 JP2019521081A JP2019521081A JP2019533449A5 JP 2019533449 A5 JP2019533449 A5 JP 2019533449A5 JP 2019521081 A JP2019521081 A JP 2019521081A JP 2019521081 A JP2019521081 A JP 2019521081A JP 2019533449 A5 JP2019533449 A5 JP 2019533449A5
- Authority
- JP
- Japan
- Prior art keywords
- soluble
- fusion protein
- protein complex
- soluble fusion
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims description 49
- 102000037865 fusion proteins Human genes 0.000 claims description 49
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 26
- 150000007523 nucleic acids Chemical group 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 210000002865 immune cell Anatomy 0.000 claims description 17
- 102000003812 Interleukin-15 Human genes 0.000 claims description 13
- 108090000172 Interleukin-15 Proteins 0.000 claims description 13
- 230000027455 binding Effects 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 230000009772 tissue formation Effects 0.000 claims description 7
- 230000001613 neoplastic effect Effects 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 102000009109 Fc receptors Human genes 0.000 claims description 4
- 108010087819 Fc receptors Proteins 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 4
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 4
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims description 4
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 229940126546 immune checkpoint molecule Drugs 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000009870 specific binding Effects 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 claims description 3
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 208000012526 B-cell neoplasm Diseases 0.000 claims description 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 230000000112 colonic effect Effects 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 102220311640 rs1382779104 Human genes 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 210000003741 urothelium Anatomy 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 239000011780 sodium chloride Substances 0.000 description 11
- 239000001509 sodium citrate Substances 0.000 description 11
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 11
- 229940038773 trisodium citrate Drugs 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 238000005406 washing Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 4
- 239000003446 ligand Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 102100033553 Delta-like protein 4 Human genes 0.000 description 2
- 101710112728 Delta-like protein 4 Proteins 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000597779 Homo sapiens Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 102000053830 human TNFSF18 Human genes 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411216P | 2016-10-21 | 2016-10-21 | |
| US62/411,216 | 2016-10-21 | ||
| US201762513964P | 2017-06-01 | 2017-06-01 | |
| US62/513,964 | 2017-06-01 | ||
| PCT/US2017/057757 WO2018075989A1 (en) | 2016-10-21 | 2017-10-21 | Multimeric il-15-based molecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019533449A JP2019533449A (ja) | 2019-11-21 |
| JP2019533449A5 true JP2019533449A5 (enExample) | 2020-10-22 |
| JP7492336B2 JP7492336B2 (ja) | 2024-05-29 |
Family
ID=62019612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019521081A Active JP7492336B2 (ja) | 2016-10-21 | 2017-10-21 | 多量体ｉｌ－１５に基づく分子 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20180200366A1 (enExample) |
| EP (2) | EP3529263B1 (enExample) |
| JP (1) | JP7492336B2 (enExample) |
| KR (2) | KR20190091264A (enExample) |
| CN (2) | CN118562016A (enExample) |
| AU (1) | AU2017345791B2 (enExample) |
| BR (1) | BR112019007920A2 (enExample) |
| CA (2) | CA3200275A1 (enExample) |
| IL (1) | IL266100B2 (enExample) |
| MX (1) | MX2019004681A (enExample) |
| SG (1) | SG11201903306SA (enExample) |
| WO (1) | WO2018075989A1 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2388266B1 (en) | 2007-05-11 | 2014-04-23 | Altor BioScience Corporation | Fusion molecules and IL-15 variants |
| EP3673915A1 (en) | 2014-06-30 | 2020-07-01 | Altor BioScience Corporation | Il-15-based molecules and methods of use thereof |
| CA3024509A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| US11472856B2 (en) | 2016-06-13 | 2022-10-18 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
| SG11201903302UA (en) | 2016-10-14 | 2019-05-30 | Xencor Inc | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments |
| US20180200366A1 (en) | 2016-10-21 | 2018-07-19 | Altor Bioscience Corporation | Multimeric il-15-based molecules |
| CA3216726C (en) * | 2017-03-06 | 2025-08-05 | Altor Bioscience Corporation | IL-15-BASED FUSION PROTEINS SPECIFIC TO IL-12 AND IL-18 |
| US11384157B2 (en) | 2017-03-20 | 2022-07-12 | Cancer Therapeutics Laboratories, Inc. | Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy |
| US11084863B2 (en) | 2017-06-30 | 2021-08-10 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains |
| US11161890B2 (en) | 2017-08-28 | 2021-11-02 | Altor Bioscience LLC. | IL-15-based fusions to IL-7 and IL-21 |
| KR20210032924A (ko) | 2017-09-05 | 2021-03-25 | 토크 테라퓨틱스, 인코포레이티드 | 치료용 단백질 조성물 및 그의 제조 및 사용 방법 |
| MX2020009472A (es) * | 2018-03-14 | 2020-12-07 | Us Health | Receptores de antigenos quimericos anti-cd33 y sus usos. |
| CN112867734A (zh) | 2018-04-18 | 2021-05-28 | Xencor股份有限公司 | 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途 |
| IL278090B2 (en) | 2018-04-18 | 2024-07-01 | Xencor Inc | Il-15/il-15rα heterodimeric fc fusion proteins and uses thereof |
| JP2021520829A (ja) | 2018-04-18 | 2021-08-26 | ゼンコア インコーポレイテッド | ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質 |
| US11311603B2 (en) | 2018-06-19 | 2022-04-26 | Nantcell, Inc. | HIV treatment compositions and methods |
| WO2020023713A1 (en) * | 2018-07-26 | 2020-01-30 | Nantbio, Inc. | Tri-cytokine txm compositions and methods |
| SG11202101779RA (en) | 2018-08-30 | 2021-03-30 | Hcw Biologics Inc | Multi-chain chimeric polypeptides and uses thereof |
| EP4592314A3 (en) | 2018-08-30 | 2025-11-05 | ImmunityBio, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| WO2020047333A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| CN118976120A (zh) * | 2018-09-07 | 2024-11-19 | 南特生物公司 | 刺激hank和nk92mi细胞的靶向il-12治疗和方法 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CA3116188A1 (en) | 2018-10-12 | 2020-04-16 | Xencor, Inc. | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof |
| KR102533540B1 (ko) | 2018-10-31 | 2023-05-17 | 난트퀘스트, 인크. | Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거(elimination of pd-l1-positive malignancies by pd-l1 chimeric antigen receptor-expressing nk cells) |
| EP3897853A1 (en) | 2018-12-20 | 2021-10-27 | Xencor, Inc. | Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains |
| WO2020146835A1 (en) * | 2019-01-11 | 2020-07-16 | Memorial Sloan Kettering Cancer Center | Multimerization of il-15/il-15r-alpha-fc complexes to enhance immunotherapy |
| WO2020243713A2 (en) * | 2019-05-31 | 2020-12-03 | City Of Hope | Cd33 targeted chimeric antigen receptor modified t cells for treatment of cd33 positive malignancies |
| CN114269903B (zh) | 2019-06-21 | 2025-11-25 | 免疫生物公司 | 多链嵌合多肽和其用途 |
| WO2021032116A1 (zh) * | 2019-08-19 | 2021-02-25 | 上海一宸医药科技有限公司 | 一种免疫细胞因子及其制备与用途 |
| EP4021928A4 (en) * | 2019-08-29 | 2023-09-20 | NantBio, Inc. | MODIFIED N-810 AND ASSOCIATED METHODS |
| RU2753282C2 (ru) * | 2019-09-19 | 2021-08-12 | Закрытое Акционерное Общество "Биокад" | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ |
| EP4041757A4 (en) * | 2019-09-26 | 2024-04-17 | Regents of the University of Minnesota | Nk engager compounds that bind viral antigens and methods of use |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| WO2021099576A1 (en) * | 2019-11-21 | 2021-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel immunotherapies targeting pd-1 with anti-pd-1/il-15 immunocytokines |
| US20210188933A1 (en) * | 2019-12-18 | 2021-06-24 | Nantcell, Inc | Methods of treating pancytopenia |
| JOP20220174A1 (ar) * | 2020-02-05 | 2023-01-30 | Novartis Ag | دايمر il-15 غير المتجانس المعبر عنه بواسطة الخلية cho |
| AU2021219720B2 (en) | 2020-02-11 | 2025-10-02 | Immunitybio, Inc. | Chromatography resin and uses thereof |
| AU2021220870A1 (en) | 2020-02-11 | 2022-08-04 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| KR20220140572A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 조절 t 세포를 활성화시키는 방법 |
| US12497462B2 (en) | 2020-04-29 | 2025-12-16 | Immunitybio, Inc. | Anti-CD26 proteins and uses thereof |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| JP2023532279A (ja) * | 2020-06-26 | 2023-07-27 | ソレント・セラピューティクス・インコーポレイテッド | 免疫調節性融合タンパク質を発現する腫瘍溶解性単純ヘルペスウイルス（ｈｓｖ） |
| US12006507B2 (en) | 2020-07-22 | 2024-06-11 | Nantcell, Inc. | Electroporation with active compensation |
| US20230280356A1 (en) * | 2020-08-03 | 2023-09-07 | Nantcell, Inc. | Drug-specific pharmacokinetic assay for il-15 superagonist |
| WO2022042576A1 (zh) * | 2020-08-27 | 2022-03-03 | 盛禾(中国)生物制药有限公司 | 一种多功能融合蛋白及其用途 |
| US20230398185A1 (en) * | 2020-10-26 | 2023-12-14 | Cytune Pharma | Il-2/il-15r-beta-gamma agonist for treating non-melanoma skin cancer |
| WO2022090203A1 (en) * | 2020-10-26 | 2022-05-05 | Cytune Pharma | IL-2/IL-15Rβү AGONIST FOR TREATING SQUAMOUS CELL CARCINOMA |
| WO2022140701A1 (en) * | 2020-12-24 | 2022-06-30 | Xencor, Inc. | Icos targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and icos antigen binding domains |
| CN112795543B (zh) * | 2021-02-04 | 2022-09-27 | 华中农业大学 | 杂交瘤细胞株及其分泌的抗草鱼IL-15Rα单克隆抗体和应用 |
| IL304916A (en) * | 2021-02-05 | 2023-10-01 | Salubris Biotherapeutics Inc | Il-15 fusion proteins and methods of making and using same |
| WO2022171195A1 (zh) * | 2021-02-11 | 2022-08-18 | 兰州大学第二医院 | 抗cd87抗体与抗pd1抗体联合治疗胃癌 |
| CN113106068A (zh) * | 2021-03-26 | 2021-07-13 | 深圳市先康达生命科学有限公司 | 一种自分泌IL-15与anti-PD1融合蛋白的免疫细胞 |
| CN117479831A (zh) * | 2021-06-09 | 2024-01-30 | 南特知识产权控股有限责任公司 | 用于在植物中生产感兴趣的蛋白质的方法和系统 |
| WO2023049832A1 (en) * | 2021-09-23 | 2023-03-30 | Sagittarius Bio, Inc. | Il-12 and il-15 polypeptides |
| US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
| CN115806629A (zh) * | 2022-08-03 | 2023-03-17 | 深圳市先康达生命科学有限公司 | 一种自分泌IL-15与anti-CTLA4结合的融合蛋白及其应用 |
| CN115806628A (zh) * | 2022-08-03 | 2023-03-17 | 深圳市先康达生命科学有限公司 | 一种自分泌IL-15与anti-TIGIT结合的融合蛋白及其应用 |
| WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
| CN116789837B (zh) * | 2023-03-24 | 2024-02-23 | 山西纳安生物科技股份有限公司 | 一种抗组织因子人源化抗体及制备的抗体偶联药物和应用 |
| CN116574192A (zh) * | 2023-03-30 | 2023-08-11 | 上海妙聚生物科技有限公司 | 一种可条件性释放并激活的细胞因子融合蛋白及其制备和用途 |
| WO2024263698A1 (en) * | 2023-06-22 | 2024-12-26 | Memorial Sloan-Kettering Cancer Center | Anti-pd-l1 immunoglobulin-related compositions comprising il-15-il-15ra fusion polypeptides and uses thereof |
| US20250243279A1 (en) | 2023-10-17 | 2025-07-31 | Xencor, Inc. | Bispecific antibodies that bind to nkp46 and mica/b |
| WO2025119308A1 (zh) * | 2023-12-08 | 2025-06-12 | 百奥泰生物制药股份有限公司 | 融合蛋白及其应用 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1975A (en) | 1841-02-12 | Manner of constructing corn-shellers | ||
| JPS5291285A (en) | 1976-01-23 | 1977-08-01 | Hitachi Ltd | Escalator |
| JPS5841623B2 (ja) | 1978-12-25 | 1983-09-13 | 株式会社東芝 | 質量分析装置のイオン検出器 |
| JPS5718916A (en) | 1980-07-11 | 1982-01-30 | Iseki Agricult Mach | Shaking table sorter of automatic feeding type thresher |
| JPS5770185A (en) | 1980-10-21 | 1982-04-30 | Kazuo Makino | Preparation of blended oil for coal liquefaction |
| JPS57144287A (en) | 1981-03-02 | 1982-09-06 | Toray Ind Inc | Cyclopentabenzofuran derivative |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| AU5098393A (en) | 1992-08-14 | 1994-03-15 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant toxin with increased half-life |
| US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| ES2151927T3 (es) | 1994-04-06 | 2001-01-16 | Immunex Corp | Interleuquina-15. |
| JPH09512165A (ja) | 1994-04-06 | 1997-12-09 | イミュネックス・コーポレーション | インターロイキン１５ |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| US7008624B1 (en) | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US5534592A (en) | 1995-09-22 | 1996-07-09 | The Goodyear Tire & Rubber Company | High performance blend for tire treads |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| DE69733610T2 (de) | 1996-04-26 | 2006-05-11 | Beth Israel Deaconess Medical Center, Inc., Boston | Interleukin-15 antagonisten |
| ATE295736T1 (de) | 1997-02-21 | 2005-06-15 | Vlaams Interuniv Inst Biotech | Verwendung von interleukin-15 |
| US6797263B2 (en) | 2000-05-12 | 2004-09-28 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
| CN101712721A (zh) | 2000-06-05 | 2010-05-26 | 阿尔托生物科学有限公司 | T细胞受体融合物及共轭物以及其使用方法 |
| DE60138222D1 (de) | 2000-09-14 | 2009-05-14 | Beth Israel Hospital | Modulierung von il-2 und il-15 vermittelten t zellantworten |
| US20030180888A1 (en) | 2000-11-03 | 2003-09-25 | Millennium Pharmaceuticals, Inc. | CD2000 and CD2001 molecules, and uses thereof |
| EP1532175B1 (en) | 2002-03-22 | 2012-10-17 | Aprogen, Inc. | Humanized antibody and process for preparing the same |
| AU2003275029A1 (en) | 2002-09-27 | 2004-04-19 | Brigham And Women's Hospital, Inc. | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues |
| EA015897B1 (ru) | 2003-02-26 | 2011-12-30 | Генмаб А/С | Применение человеческого моноклонального антитела к ил-15 в составе композиции и лекарственного препарата (варианты), композиция и лекарственный препарат, его включающие |
| DE10324708A1 (de) | 2003-05-30 | 2004-12-16 | Ltn Servotechnik Gmbh | Schleifringelement und Verfahren zu dessen Herstellung |
| CN1233822C (zh) | 2003-09-05 | 2005-12-28 | 中国科学技术大学 | 白细胞介素－15基因修饰的自然杀伤细胞株及其制备方法 |
| CN105021814B (zh) | 2003-11-10 | 2018-02-16 | 阿尔特生物科学公司 | 可溶性tcr分子及其用途 |
| EP1718670B1 (en) | 2004-02-27 | 2011-07-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Il-15 binding site for il 15-ralpha and specific il-15 mutants having agonist/antagonist activity |
| EP1586585A1 (de) | 2004-04-14 | 2005-10-19 | F. Hoffmann-La Roche Ag | Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung |
| CN100334112C (zh) | 2004-10-15 | 2007-08-29 | 上海海欣生物技术有限公司 | 人白细胞介素15与Fc融合蛋白 |
| PT1814580T (pt) | 2004-11-24 | 2016-11-11 | Hutchinson Fred Cancer Res | Métodos de utilização de il-21 para imunoterapia adotiva e identificação de antigénios tumorais |
| NZ555590A (en) | 2004-12-13 | 2009-07-31 | Cytos Biotechnology Ag | Compositions comprising a VLP and IL-15 protein |
| US8124084B2 (en) | 2005-05-17 | 2012-02-28 | University Of Connecticut | Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| EP1873166B1 (en) | 2006-06-30 | 2010-09-08 | CONARIS research institute AG | Improved sgp 130Fc dimers |
| US7965180B2 (en) | 2006-09-28 | 2011-06-21 | Semiconductor Energy Laboratory Co., Ltd. | Wireless sensor device |
| JP5840837B2 (ja) | 2007-03-30 | 2016-01-06 | メモリアル スローン−ケタリング キャンサー センター | 養子移入ｔリンパ球における副刺激リガンドの構成性発現 |
| EP2388266B1 (en) | 2007-05-11 | 2014-04-23 | Altor BioScience Corporation | Fusion molecules and IL-15 variants |
| AU2013273643C1 (en) | 2007-05-11 | 2016-08-11 | Altor Bioscience Corporation | Fusion molecules and il-15 variants |
| CA2691539C (en) | 2007-06-21 | 2014-08-26 | Angelica Therapeutics, Inc. | Modified toxins |
| EP2724727A1 (en) | 2007-06-27 | 2014-04-30 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Complexes of IL-15 and IL-15R alpha and uses thereof |
| US7837588B2 (en) | 2007-07-20 | 2010-11-23 | American Axle & Manufacturing, Inc. | Pre-load mechanism for helical gear differential |
| US20110070191A1 (en) | 2008-03-19 | 2011-03-24 | Wong Hing C | T cell receptor fusions and conjugates and methods of use there of |
| US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
| JP6251570B2 (ja) | 2010-09-21 | 2017-12-20 | アルター・バイオサイエンス・コーポレーション | 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法 |
| EP2537933A1 (en) * | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| US20130302274A1 (en) | 2011-11-25 | 2013-11-14 | Roche Glycart Ag | Combination therapy |
| WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| WO2013189901A1 (en) | 2012-06-18 | 2013-12-27 | Novartis Ag | Stabilized gp120 |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| WO2014028776A1 (en) | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| EA201992107A1 (ru) | 2012-10-18 | 2020-04-30 | Рокфеллер Юниверсити (Дзе) | Нейтрализующие анти-вич-антитела широкого спектра действия |
| JP6359019B2 (ja) | 2012-10-24 | 2018-07-18 | ノバルティス アーゲー | ＩＬ−１５Ｒα型、ＩＬ−１５Ｒα型を発現する細胞、ならびにＩＬ−１５ＲαおよびＩＬ−１５／ＩＬ−１５Ｒα複合体の治療上の使用 |
| CA3193936A1 (en) * | 2014-01-15 | 2015-07-23 | Kadmon Corporation, Llc | Immunomodulatory agents |
| EP3673915A1 (en) | 2014-06-30 | 2020-07-01 | Altor BioScience Corporation | Il-15-based molecules and methods of use thereof |
| CN104672325A (zh) | 2015-03-11 | 2015-06-03 | 福建农林大学 | 一种用新鲜螺旋藻制备藻蓝蛋白的方法 |
| EP3271389B8 (en) | 2015-03-20 | 2020-04-22 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Neutralizing antibodies to gp120 and their use |
| CN108463239A (zh) | 2015-09-25 | 2018-08-28 | 阿尔托生物科学有限公司 | 白介素-15超激动剂显著提升移植物抗肿瘤活性 |
| AU2017271593B2 (en) | 2016-05-27 | 2021-04-22 | Altor Bioscience Corporation | Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains |
| US20180200366A1 (en) | 2016-10-21 | 2018-07-19 | Altor Bioscience Corporation | Multimeric il-15-based molecules |
| EP3773657A4 (en) | 2018-03-26 | 2021-12-08 | Altor Bioscience LLC | ANTI-PDL1, IL-15 AND TGF BETA RECEPTOR COMBINATION MOLECULES |
-
2017
- 2017-10-21 US US15/789,985 patent/US20180200366A1/en not_active Abandoned
- 2017-10-21 AU AU2017345791A patent/AU2017345791B2/en active Active
- 2017-10-21 KR KR1020197014404A patent/KR20190091264A/ko not_active Ceased
- 2017-10-21 BR BR112019007920A patent/BR112019007920A2/pt unknown
- 2017-10-21 JP JP2019521081A patent/JP7492336B2/ja active Active
- 2017-10-21 EP EP17861811.2A patent/EP3529263B1/en active Active
- 2017-10-21 CA CA3200275A patent/CA3200275A1/en active Pending
- 2017-10-21 CN CN202410633109.2A patent/CN118562016A/zh active Pending
- 2017-10-21 EP EP25187905.2A patent/EP4613776A3/en active Pending
- 2017-10-21 CN CN201780079905.4A patent/CN110799528B/zh active Active
- 2017-10-21 SG SG11201903306SA patent/SG11201903306SA/en unknown
- 2017-10-21 WO PCT/US2017/057757 patent/WO2018075989A1/en not_active Ceased
- 2017-10-21 KR KR1020217015704A patent/KR102392142B1/ko active Active
- 2017-10-21 CA CA3041310A patent/CA3041310C/en active Active
- 2017-10-21 MX MX2019004681A patent/MX2019004681A/es unknown
-
2019
- 2019-04-17 IL IL266100A patent/IL266100B2/en unknown
-
2020
- 2020-01-24 US US16/752,606 patent/US11369679B2/en active Active
-
2021
- 2021-01-29 US US17/163,239 patent/US11318201B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019533449A5 (enExample) | ||
| US20190070262A1 (en) | Interleukin-18 variants and methods of use | |
| KR102247704B1 (ko) | 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법 | |
| CN112028996A (zh) | 靶向bcma的单域抗体及其用途 | |
| JP2020515518A5 (enExample) | ||
| US20210253659A1 (en) | Il-17a-binding polypeptides | |
| US11993655B2 (en) | Anti-PD-L1 antibody and use thereof | |
| JP2019506841A5 (enExample) | ||
| CN111378044B (zh) | 抗体融合蛋白、制备方法及其应用 | |
| JP2017519503A5 (enExample) | ||
| JP2020536586A (ja) | ＩｇＧ１ Ｆｃモノマー、及びその使用 | |
| CN113943370A (zh) | 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法 | |
| CN110981958A (zh) | 一种pd-l1抗体 | |
| CA3157611A1 (en) | Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof | |
| JP2021505663A5 (enExample) | ||
| CN115605513A (zh) | 一种抗pd-l1和her2的双特异性抗体 | |
| AU2018358138A1 (en) | Bispecific antibodies and methods of making and using thereof | |
| JP2020535811A5 (enExample) | ||
| JP2018525347A (ja) | 癌免疫療法に使用するための二重特異性抗体 | |
| JP7365654B2 (ja) | 抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体 | |
| JPWO2019147670A5 (enExample) | ||
| JP2021534750A (ja) | 新規ながん免疫療法抗体組成物 | |
| CN118108842A (zh) | 人源化抗cd24抗体及其应用 | |
| WO2023066401A1 (zh) | 一种特异性结合人ctla4的抗体及包含其的药物和试剂盒 | |
| CN109879965B (zh) | 抗epha2单链抗体、抗cd3e单链抗体及融合蛋白及其应用 |